- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Ipilimumab for Early-Stage Melanoma?
Despite promising results, experts believe it's too early to use ipilimumab for early-stage melanoma, high toxicity being one of the limiting factors.
The drug is
for use in stage IV disease.
For the first time, ipilimumab (Yervoy, Bristol-Myers Squibb) has been shown to be effective in an adjuvant setting for earlier-stage melanoma. already approved
Results presented here at the 2014 Annual Meeting of the American Society of Clinical Oncology® show that ipilimumab significantly delayed recurrence, compared with placebo, in these stage III patients.
In a new study, known as EORTC 18071, more than 900 patients with stage III disease received ipilimumab (10 mg/kg) at a dose higher than the dose approved (3 mg/kg) for stage IV disease.
But experts say that these results are not strong enough to catapult the immunotherapy into the role of an important treatment option in this setting. And they cite the drug's toxicity as an ongoing concern, given the marginal benefit shown so far.
Read the original report here:
Source: Medscape
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
